文献速递脊柱关节炎

抗TNF与csDMARD对银屑病关节炎工作障碍及临床结局的影响

Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

6个月时抗TNF组工作生产力改善更快更大,临床应答也明显优于csDMARD组。

要点

  • 抗TNF组6个月出勤主义改善30%、工作生产力改善40%,均P<0.001。
  • csDMARD组出勤主义改善10%(P=0.007)、工作生产力改善15%(P=0.001)。
  • csDMARD组DAPSA改善8.4分,抗TNF组改善36.8分,均P<0.001。

核心结论

  • 在真实世界中,活动性PsA患者起始抗TNF治疗后工作障碍与临床结局均获显著且有临床意义的改善。
  • 起始csDMARD者的各项结局改善更慢且幅度更小。

研究设计与样本

  • 工作障碍采用工作生产力与活动特异性健康问题工具测量,外周关节活动度采用DAPSA复合指标测量。

主要发现

  • 6个月时csDMARD组(n=164)出勤主义改善10%(P=0.007)、工作生产力改善15%(P=0.001)。
  • 抗TNF组(n=65)出勤主义改善30%(P<0.001)、工作生产力改善40%(P<0.001)。
  • csDMARD组(n=272)DAPSA改善8.4分(P<0.001),抗TNF组(n=121)改善36.8分(P<0.001)。

临床怎么用

  • 对活动性PsA伴工作障碍者,抗TNF治疗可能带来更快更大的工作生产力与临床改善。
  • csDMARD治疗者结局改善较慢较小,需关注其工作障碍的持续评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the effect of medical treatment on work disability in patients with active PsA in a real-world setting. METHODS: Four hundred patients with active PsA commencing or switching to anti-TNF or conventional synthetic DMARD (csDMARD) were recruited to a multicentre UK prospective observational cohort study. Work disability was measured using the work productivity and activity-specific health problem instrument and peripheral joint activity was measured with the disease activity in PsA composite measure. RESULTS: Four hundred patients were recruited, of whom 229 (57.25%) were working (of any age). Sixty-two patients of working age (24%) were unemployed. At 6 months there was a 10% improvement in presenteeism ( P = 0.007) and a 15% improvement in work productivity ( P = 0.001) among working patients commenced on csDMARDs ( n = 164) vs a larger and more rapid 30% improvement in presenteeism ( P < 0.001) and 40% improvement in work productivity ( P < 0.001) among those commenced on anti-TNF therapy ( n = 65). Clinical response was poor among patients commenced on a csDMARD ( n = 272), with an 8.4 point improvement in disease activity in PsA ( P < 0.001) vs those commenced on anti-TNF therapy ( n = 121), who had a 36.8 point improvement ( P < 0.001). CONCLUSION: We report significant and clinically meaningful improvements in both work disability and clinical outcomes after commencement of anti-TNF therapy in a real-world setting. Improvements in all outcomes among those commencing csDMARDs were slower and of a smaller magnitude.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Tillett W, Shaddick G, Jobling A, et al. Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. Rheumatology (Oxford). 2017. PMID: 28013211. doi:10.1093/rheumatology/kew433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。